Quick Answer
Tenaya Therapeutics, Inc. reported Cash and Equivalents of $100.55 million for fiscal year 2025.
Tenaya Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $100.55M | +2225.9% |
| 2024 | $4.32M | -90.5% |
| 2023 | $45.68M | -52.1% |
| 2022 | $95.27M | +149.9% |
| 2021 | $38.13M | -70.3% |
| 2020 | $128.53M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $56.31M | +584.1% | -10.1% |
| June 30, 2025 | $62.67M | +7.8% | +16.5% |
| March 31, 2025 | $53.77M | -9.3% | +1143.9% |
| December 31, 2024 | $4.32M | -90.5% | -47.5% |
| September 30, 2024 | $8.23M | -90.0% | -85.8% |
| June 30, 2024 | $58.13M | -23.1% | -2.0% |
| March 31, 2024 | $59.30M | -18.3% | +29.8% |
| December 31, 2023 | $45.68M | -52.1% | -44.4% |
- Tenaya Therapeutics, Inc. showed an increase of +2225.9% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Tenaya Therapeutics, Inc.’s cash and equivalents has declined by 21.8% (from $128.53 million to $100.55 million).
- The most recent figure is from Tenaya Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: